Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
A new study finds that the gabapentin, used to treat chronic pain and nerve pain, was associated with fewer fall-related health care visits. The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.2% from 2025 to 2030. THURSDAY, Jan. 9, 2025 (HealthDay News) -- A pain-relieving medication might be safer for seniors than first thought. A new study published Jan. 7 in the Annals of Internal Medicine says Gabapentin is widely used to help treat chronic pain and nerve pain, particularly as an alternative to opioid painkillers. The drug is the sixth-most prescribed in the U.S. (photo by Hush Naidoo Jade Photography via Unsplash) Hush Naidoo Jade Photography In a seminal trial on pain following shingles (post-herpetic neuralgia), the target dose of gabapentin was 900 mg four times daily. Mary Peart, 67, a retired nurse in Manchester-by-the-Sea, Mass., began taking gabapentin a year and a half ago to reduce the pain and fatigue of fibromyalgia. At 6-month follow-up, incident gabapentin users had lower hazard of falls (hazard ratio, 0.52 [95% CI, 0.43 to 0.64]), but there was no difference in the hazards of experiencing severe falls. Results were similar across sensitivity and subgroup analyses. Using data from a large national survey, Johansen found that 4.7% of U.S. adults were prescribed a gabapentinoid in 2021, up from 4% in 2015 – a statistically significant increase of 17.5% in six years. The growth was primarily driven by gabapentin, as there was little change in pregabalin’s use. Incident use of gabapentin is not associated with an increase in fall-related hospital visits compared with duloxetine use, according to a study published online Jan. 7 in the Annals of Internal A March 1, 2025, reporting date for veterinarians was established in a law passed in 2023 as part of an effort to reduce harmful interactions of gabapentin and opioids in people. Pharmacies were required to report on gabapentin starting in 2024. If dispensed in a compounded preparation in dosages of 100 mg or less, gabapentin need not be reported. New use of gabapentin (Neurontin) was not associated with greater risk of falls in older adults with neuropathy or fibromyalgia compared with new use of duloxetine (Cymbalta), a commercial This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated 10 Mar 2025), Cerner Multum™ (updated 23 Mar 2025), ASHP (updated 12 Mar 2025) and others. Gabapentinoids such as gabapentin and pregabalin are anticonvulsant drugs that are retrieved 26 March 2025 Daily science news on research developments and the latest scientific innovations A March 1, 2025, reporting date for veterinarians was established in a law passed in 2023 as part of an effort to reduce harmful interactions of gabapentin and opioids in people. Pharmacies were required to report on gabapentin starting in 2024. If dispensed in a compounded preparation in dosages of 100 mg or less, gabapentin need not be reported. TUESDAY, Jan. 7, 2025 -- Incident use of gabapentin is not associated with an increase in fall-related hospital visits compared with duloxetine use, according to a study published online Jan. 7 in the Annals of Internal Medicine. The investigators advised that the growth in use was primarily driven by gabapentin, and no increase in pregabalin users was detected after 2008 or after generic availability in 2019. Research at UC San Francisco has shown for the first time how the commonly prescribed seizure and pain medication, gabapentin, acts inside of cells, opening the door to new, more effective What is gabapentin? Gabapentin is a prescription medication that was approved by the U.S. Food and Drug Administration in 1993 as a treatment for epilepsy. It works by binding to a type of calcium THURSDAY, Jan. 9, 2025 (HealthDay News) -- A pain-relieving medication might be safer for seniors than first thought. A new study published Jan. 7 in the Annals of Internal Medicine says gabapentin immediate ‐ release capsule or tablet; or gabapentin extended ‐ release 300 mg or 600 mg tablet Drug Formulary I, Drug Formulary II, Drug Formulary III: Gralise 750mg tablet. Tier 3, ST: NF. 3/1/2024: gabapentin immediate ‐ release capsule or tablet; or gabapentin extended ‐ release 300 mg or 600 mg tablet Drug Formulary I
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |